Virtu Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Virtu Financial’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,645	Closed	-$336K	–	1587
2022 Q1	$336K	Buy	+20,645	New	+$331K	0.02%	537
2021 Q3	–	Sell	-34,159	Closed	-$540K	–	1509
2021 Q2	$540K	Buy	+34,159	New	+$464K	0.05%	433
2020 Q3	–	Sell	-23,568	Closed	-$112K	–	1063
2020 Q2	$112K	Buy	+23,568	New	+$94.1K	0.01%	853
2019 Q4	$269K	Buy	77,838 +60,978	+362%	+$153K	0.03%	747
2019 Q3	$48K	Buy	+16,860	New	+$52.4K	﹤0.01%	1199
2018 Q2	–	Sell	-11,374	Closed	-$54K	–	1981
2018 Q1	$54K	Buy	+11,374	New	+$58.4K	﹤0.01%	1697

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial's BCRX Position: Q2 2022 in Review

Virtu Financial sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 20,645 shares — an estimated $336K sold.

Virtu Financial first reported a position in BCRX in Q1 2018 and held it in 6 quarters. The position peaked at $540K in Q2 2021. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

Virtu Financial reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Virtu Financial sold 20,645 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $336K.
Virtu Financial first reported a position in BioCryst Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Virtu Financial's BioCryst Pharmaceuticals position peaked at $540K in Q2 2021.
221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Virtu Financial's 13F filing for Q2 2022, filed 9 Aug 2022.